New treatments for age-related macular degeneration.
Imrie
Fraser R
FR
Bristol Eye Hospital, Lower Maudlin Street, Bristol, BS1 2LX, UK. fraser.imrie@ubht.nhs.uk
Bailey
Clare
C
D000368:Aged; D000369:Aged, 80 and over; D000375:Aging / Q000473:pathology*; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D052157:Aptamers, Nucleotide / Q000627:therapeutic use; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000473:pathology / Q000628:therapy; D006801:Humans; D008028:Light Coagulation; D008268:Macular Degeneration / Q000473:pathology* / Q000628:therapy*; D010778:Photochemotherapy; D016032:Randomized Controlled Trials as Topic; D000069579:Ranibizumab; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D052157:Aptamers, Nucleotide; D042461:Vascular Endothelial Growth Factor A; C495058:pegaptanib; D000068258:Bevacizumab; D000069579:Ranibizumab